Compare Manhattan Associates Inc (MANH) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manhattan Associates Inc vs McKesson Corporation — how do they compare? Manhattan Associates Inc trades at $206.57 (market cap $12.06B), while McKesson Corporation trades at $931.59 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 9× Manhattan Associates Inc's market cap, and McKesson Corporation pays a 0.4% dividend while Manhattan Associates Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manhattan Associates Inc for 12 Days and McKesson Corporation for 74 Days on average.
| MANH | MCK | |
|---|---|---|
Market Cap | $12.06B | $108.46B |
Volume | 376,150 | 712,607 |
Sector | Technology | Health |
52-Week High | $223.76 | $995.69 |
52-Week Low | $120.88 | $725.17 |
Typical Hold Time | 12 Days | 74 Days |
Enterprise Value | $11.93B | $115.00B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manhattan Associates (MANH) trades at $202.11, down 0.36% with bearish technical signals but strong fundamentals. The stock shows robust profitability with 18.67% net margins and consistent earnings beats, though valuation multiples appear elevated. Recent news includes a law firm investigation into fiduciary duties and a downgrade to neutral by DA Davidson, while the company launched new solution editions to expand market reach.
The outlook balances strong operational performance against high valuation and legal scrutiny. Upside potential exists from continued earnings momentum and product innovation, but risks include the ongoing investigation and competitive pressures. Analyst consensus remains bullish with a $210.50 price target, suggesting modest upside from current levels.
McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.
The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
